Tonic Activation of NR2D-Containing NMDARs Exacerbates Dopaminergic Neuronal Loss in MPTP-Injected Parkinsonian Mice

Ramesh Sharma1,2,3, Chiranjivi Neupane1,2,3, Thuy Linh Pham1,2

  • 1Department of Biomedicine, Chungnam National University, Daejeon 35015, Republic of Korea.

Insights

MPTP intoxication recruits NR2D subunits in midbrain dopaminergic neurons, causing a persistent NMDA current that exacerbates neuronal loss and gait deficits in Parkinsonism models.

Area of Science:

  • Neuroscience
  • Neuropharmacology
  • Molecular Biology

Background:

  • NR2D subunit-containing NMDA receptors (NMDARs) are developmentally regulated, decreasing with brain maturation.
  • These receptors can be recruited in adult brains by specific pathophysiological stimuli.
  • Dopaminergic (DA) neurons in the midbrain are crucial for motor control and are affected in Parkinson's disease.

Purpose of the Study:

  • To investigate the role of NR2D subunit-containing NMDARs in MPTP-induced Parkinsonism.
  • To determine if MPTP intoxication recruits NR2D subunits in midbrain DA neurons.
  • To assess the therapeutic potential of targeting NR2D subunits in Parkinson's disease.

Main Methods:

  • MPTP intoxication model in mature male mice.
  • Electrophysiological recordings to measure NMDA currents (INMDA) in DA neurons.
  • Pharmacological and genetic manipulation of NR2D subunits.
  • Assessment of DA neuronal loss and gait deficits.

Main Results:

  • MPTP intoxication selectively recruited NR2D-NMDARs in midbrain DA neurons (SNpc and VTA).
  • This recruitment generated a magnesium (Mg2+)-resistant tonic NMDA current (INMDA).
  • MPTP increased NR2D expression in midbrain regions.
  • Intervention targeting NR2D abolished the tonic INMDA, attenuated DA neuronal loss, and improved gait deficits.

Conclusions:

  • Extrasynaptic NR2D recruitment generates a Mg2+-resistant tonic INMDA, exacerbating DA neuronal death in MPTP-induced Parkinsonism.
  • NR2D subunit-containing NMDARs are a key contributor to MPTP-induced neurodegeneration and motor symptoms.
  • State-dependent NR2D recruitment represents a potential therapeutic target for neuroprotection in Parkinson's disease and other neurodegenerative disorders.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
592
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K